{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:18:38Z","timestamp":1785860318094,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["01-10026 \/ 0010396\/ 01\/ 221 \/ 221\/ 0 \/ 2026;"],"award-info":[{"award-number":["01-10026 \/ 0010396\/ 01\/ 221 \/ 221\/ 0 \/ 2026;"]}],"id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s43440-026-00867-1","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T09:17:41Z","timestamp":1779268661000},"page":"1292-1300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment-emergent psychiatric adverse events in patient-reported outcomes during ketamine use for major depressive disorder: a retrospective analysis"],"prefix":"10.1007","volume":"78","author":[{"given":"Aleksander","family":"Kwa\u015bny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Wilkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Jerzy","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"17","key":"867_CR1","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1111\/bph.15596","volume":"179","author":"M Papp","year":"2022","unstructured":"Papp M, Cubala WJ, Swiecicki L, Newman-Tancredi A, Willner P. Perspectives for therapy of treatment-resistant depression. Br J Pharmacol. 2022;179(17):4181\u2013200. https:\/\/doi.org\/10.1111\/bph.15596. PubMed PMID: 34128229.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"867_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/ijnp\/pyaa033","volume":"23","author":"RW Taylor","year":"2020","unstructured":"Taylor RW, Marwood L, Oprea E, Deangel V, Mather S, Valentini B, et al. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. Int J Neuropsychopharmacol. 2020;23(9):587\u2013625. https:\/\/doi.org\/10.1093\/ijnp\/pyaa033. PubMed PMID: 32402075.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"867_CR3","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS, Ketamine. A Paradigm Shift for Depression Research and Treatment. Neuron. 2019;101(5):774\u20138. https:\/\/doi.org\/10.1016\/J.NEURON.2019.02.005. PubMed PMID: 30844397.","journal-title":"Neuron"},{"key":"867_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/978-981-33-6044","volume":"1305","author":"M Fornaro","year":"2021","unstructured":"Fornaro M, De Berardis D, Anastasia A, Fusco A. Novel Psychopharmacology for Depressive Disorders. Adv Exp Med Biol. 2021;1305:449\u201361. https:\/\/doi.org\/10.1007\/978-981-33-6044. -0_22 PubMed PMID: 33834412.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"867_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/APPI","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. Am J Psychiatry. 2018;175(2):150\u20138. https:\/\/doi.org\/10.1176\/APPI.AJP.2017.17040472. PubMed PMID: 28969441.","journal-title":"Am J Psychiatry"},{"key":"867_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.euroneuro.2024.04.014","volume":"86","author":"A Kwa\u015bny","year":"2024","unstructured":"Kwa\u015bny A, Kwa\u015bna J, Wilkowska A, Szarmach J, S\u0142upski J, W\u0142odarczyk A, et al. Ketamine treatment for anhedonia in unipolar and bipolar depression: a systematic review. Eur Neuropsychopharmacol. 2024;86:20\u201334. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.04.014. PubMed PMID: 38917771.","journal-title":"Eur Neuropsychopharmacol"},{"key":"867_CR7","doi-asserted-by":"publisher","unstructured":"Brody BD, Popeo DM, Smetana RW, Kanellopoulos D. How do we get ketamine safety right? Three questions from a clinical service. J Clin Psychiatry. 2025;86(3). https:\/\/doi.org\/10.4088\/JCP.25COM15946. PubMed PMID: 40673898.","DOI":"10.4088\/JCP.25COM15946"},{"issue":"1","key":"867_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S0033291709006011","volume":"40","author":"AA Nierenberg","year":"2009","unstructured":"Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2009;40(1):41. https:\/\/doi.org\/10.1017\/S0033291709006011. PubMed PMID: 19460188.","journal-title":"Psychol Med"},{"issue":"2","key":"867_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/JCP.0b013e31820ebd2","volume":"31","author":"SM McClintock","year":"2011","unstructured":"McClintock SM, Husain MM, Wisniewski SR, Nierenberg AA, Stewart JW, Trivedi MH, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180\u20136. https:\/\/doi.org\/10.1097\/JCP.0b013e31820ebd2c.\u00a0 PubMed PMID: 21346613.","journal-title":"J Clin Psychopharmacol"},{"key":"867_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jad.2017.05.048","volume":"221","author":"GM Goodwin","year":"2017","unstructured":"Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017;221:31\u20135. https:\/\/doi.org\/10.1016\/j.jad.2017.05.048. PubMed PMID: 28628765.","journal-title":"J Affect Disord"},{"issue":"3","key":"867_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/wps.21120","volume":"22","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394. 10. 1002\/WPS.21120 PubMed PMID: 37713549.","journal-title":"World Psychiatry"},{"key":"867_CR12","doi-asserted-by":"publisher","unstructured":"S\u0142upski J, Cuba\u0142a WJ, G\u00f3rska N, S\u0142upska A, Ga\u0142uszko-W\u0119gielnik M. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression. Med Hypotheses. 2020;144. https:\/\/doi.org\/10.1016\/j.mehy.2020.110268. PubMed PMID: 33254572.","DOI":"10.1016\/j.mehy.2020.110268"},{"key":"867_CR13","doi-asserted-by":"publisher","unstructured":"Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report(QIDS-SR) in public sector patients with mood disorders: a psyc\u2026 Psychol Med. 2004;34(1):73\u201382. https:\/\/doi.org\/10.1017\/S0033291703001107. PubMed PMID: 14971628.","DOI":"10.1017\/S0033291703001107"},{"key":"867_CR14","unstructured":"International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline for Good Clinical Practice E6(R3). https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf. Accessed 7 April 2026."},{"issue":"29","key":"867_CR15","doi-asserted-by":"publisher","first-page":"e26769","DOI":"10.1097\/MD.0000000000026769","volume":"100","author":"A W\u0142odarczyk","year":"2021","unstructured":"W\u0142odarczyk A, Cuba\u0142a WJ, Ga\u0142uszko-W\u0229gielnik M, Szarmach J. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. Medicine. 2021;100(29):e26769. https:\/\/doi.org\/10.1097\/MD.0000000000026769. PubMed PMID: 34398056.","journal-title":"Medicine"},{"issue":"6","key":"867_CR16","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s43440-024-00641-1","volume":"76","author":"A Kwa\u015bny","year":"2024","unstructured":"Kwa\u015bny A, Cuba\u0142a WJ, W\u0142odarczyk A, Pastuszak K. Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment. Pharmacol Rep. 2024;76(6):1325\u201332. https:\/\/doi.org\/10.1007\/s43440-024-00641-1. PubMed PMID: 39207673.","journal-title":"Pharmacol Rep"},{"key":"867_CR17","doi-asserted-by":"publisher","unstructured":"Duncan WC, Zarate CA. Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep. 2013;15(9). https:\/\/doi.org\/10.1007\/S11920-013-0394-Z.\u00a0 PubMed PMID: 23949569.","DOI":"10.1007\/S11920-013-0394-Z"},{"key":"867_CR18","doi-asserted-by":"publisher","first-page":"1616859","DOI":"10.3389\/FNUT.2025.1616859\/FULL","volume":"12","author":"J S\u0142upski","year":"2025","unstructured":"S\u0142upski J, Mechli\u0144ska A, W\u0142odarczyk A, Kwa\u015bny A, Szarmach J, S\u0142upska A, et al. Appetite measures as correlates of clinical response in mood disorders treated with ketamine: systematic review. Front Nutr. 2025;12:1616859. https:\/\/doi.org\/10.3389\/FNUT.2025.1616859\/FULL.","journal-title":"Front Nutr"},{"issue":"5","key":"867_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/acps.13216","volume":"142","author":"LT Park","year":"2020","unstructured":"Park LT, Luckenbaugh DA, Pennybaker SJ, Hopkins MA, Henter ID, Lener MS, et al. The effects of ketamine on typical and atypical depressive symptoms. Acta Psychiatr Scand. 2020;142(5):394\u2013401. 10. 1111\/ACPS.13216 PubMed PMID: 32677051.","journal-title":"Acta Psychiatr Scand"},{"key":"867_CR20","doi-asserted-by":"publisher","unstructured":"Pastuszak M, Cuba\u0142a WJ, Kwa\u015bny A. Treatment-emergent symptoms during short-term ketamine administration in treatment-resistant bipolar depression: A retrospective cross-sectional descriptive study. Asian J Psychiatr. 2024;99. https:\/\/doi.org\/10.1016\/j.ajp.2024.104159. PubMed PMID: 39018703.","DOI":"10.1016\/j.ajp.2024.104159"},{"key":"867_CR21","doi-asserted-by":"publisher","unstructured":"Gutierrez G, Kang MJY, Vazquez G. IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital. Psychiatry Res. 2024;335. https:\/\/doi.org\/10.1016\/j.psychres.2024.115865. PubMed PMID: 38518518.","DOI":"10.1016\/j.psychres.2024.115865"},{"key":"867_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.jad.2020.07","volume":"276","author":"M Fornaro","year":"2020","unstructured":"Fornaro M, Carvalho AF, Fusco A, Anastasia A, Solmi M, Berk M, et al. The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. J Affect Disord. 2020;276:970\u201383. https:\/\/doi.org\/10.1016\/j.jad.2020.07.109. PubMed PMID: 32750614.","journal-title":"J Affect Disord"},{"issue":"5","key":"867_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021;178(5):383. 10.1176\/. APPI.AJP.2020.20081251 PubMed PMID: 33726522.","journal-title":"Am J Psychiatry"},{"key":"867_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jad.2024.01.207","volume":"351","author":"BD Brody","year":"2024","unstructured":"Brody BD, Park N, Christian A, Shaffer CW, Smetana R, Kotbi N, et al. Ketamine for major depressive disorder during an inpatient psychiatric admission: Effectiveness, adverse events, and lessons learned. J Affect Disord. 2024;351:293\u20138. https:\/\/doi.org\/10.1016\/j.jad.2024.01.207. PubMed PMID: 38286230.","journal-title":"J Affect Disord"},{"key":"867_CR25","doi-asserted-by":"publisher","unstructured":"Bhatt K, Yoo J, Bridges A. Ketamine-induced manic episode. Prim Care Companion CNS Disord. 2021;23(3). https:\/\/doi.org\/10.4088\/PCC.20L02811. PubMed PMID: 34000155.","DOI":"10.4088\/PCC.20L02811"},{"issue":"7","key":"867_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/0269881113486718","volume":"27","author":"MJ Niciu","year":"2013","unstructured":"Niciu MJ, Grunschel BDG, Corlett PR, Pittenger C, Bloch MH. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol. 2013;27(7):651\u20134. https:\/\/doi.org\/10.1177\/0269881113486718; WGROUP:STRING:PUBLICATION. PubMed PMID: 23676198.","journal-title":"J Psychopharmacol"},{"key":"867_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","volume":"120","author":"H Gill","year":"2021","unstructured":"Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, et al. The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78\u201385. https:\/\/doi.org\/10.1016\/J.NEUBIOREV.2020.11.020. PubMed PMID: 33242561.","journal-title":"Neurosci Biobehav Rev"},{"key":"867_CR28","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/J.JAD.2023.10.120","volume":"345","author":"N Hovda","year":"2024","unstructured":"Hovda N, Gerrish W, Frizzell W, Shackelford R. A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. J Affect Disord. 2024;345:262\u201371. https:\/\/doi.org\/10.1016\/J.JAD.2023.10.120. PubMed PMID: 37875227.","journal-title":"J Affect Disord"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00867-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00867-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:21:56Z","timestamp":1785856916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00867-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["867"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00867-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Krzysztof Pastuszak has no conflict of interestMicha\u0142 Pastuszak received research support from Beckley Psytech, Compass Pathways, Definium Therapeutics, GH Research, MSD. Aleksander Kwa\u015bny received research support from Beckley Psytech, Compass Pathways, Definium Therapeutics, GH Research, MSD. Alina Wilkowska has received research support from Angelini, Biogen, Eli Lilly and Company, Janssen- Cilag, Lundbeck, Polpharma, Sanofi, Termedia, Valeant, Bristol Myers Squibb.Wies\u0142aw Jerzy Cuba\u0142a has received grants: Acadia, Alkermes, Allergan, Angelini, Auspex Pharmaceuticals, Beckley Psytech, BMS, Celon, Cephalon, Compass Pathways, Cortexyme, Ferrier, Forest Laboratories, GedeonRichter, GH Research, GWPharmaceuticals, HMNC Brain Health, IntraCellular Therapies, Janssen, KCR, Lilly, Lundbeck, MindMed (Definium), Minerva, MSD, NIH, Neumora, Novartis, Orion, Otsuka, Recognify Life Sciences, Sanofi, Seaport, Servier; Honoraria: Adamed, Angelini, AstraZeneca, BMS, Celon, GH Research, GSK, Janssen, KRKA, Lekam, Lundbeck, Minerva, NeuroCog, Novartis, Orion, Pfizer, Polfa Tarchomin, Sanofi, Servier, Zentiva; Advisory boards: Angelini, Celon (ended 2021), Douglas Pharmaceuticals, GH Research, Janssen, MSD, Novartis, Polpharma, Sanofi, Tasman Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}